ASReview vs EviSynth

ASReview is a free, open-source tool that uses AI-aided active learning to prioritize records for systematic review screening, with a human making screening decisions. Its site says the approach can reduce screening workload by up to 95%. Users can simulate AI-aided review to compare models, while Crowdscreen supports parallel screening with access managed by administrators through a private login system. The described model families are ELAS-Ultra, ELAS-Heavy, and language-agnostic ELAS-L; ELAS-Heavy and ELAS-L require the Dory package. ASReview works with reference managers including EndNote and PubMed, and imports and exports CSV, RIS, and XLSX files. Documentation includes a Python API, while the institutional workflow also describes a REST API and CLI for automation. In a local setup, data stays on the user's computer; server deployments keep it in the organization's environment and follow its policies. Support includes documentation, tutorials, videos, community discussion, and organizational workshops and consultancy. ASReview LAB costs nothing with no licensing fees or subscriptions, though running hardware or a server may incur costs.

EviSynth is a platform for evidence syntheses and systematic reviews, available on Android, iOS, and the web. Its screening workflow uses a language model to assess abstracts against PICO criteria and suggest inclusion or exclusion. Built-in risk-of-bias tools support RoB 2, ROBINS-I, and custom checklists. Teams can invite collaborators, resolve conflicts, and track who screened each item and when. The AI Insights tab provides summaries, keyword extraction, and bias hints. References can be imported as EndNote XML or PubMed NBIB files, and the screening interface is designed for touch-screen use on mobile devices. The maker describes access as free for academic use, with no trials or subscriptions, and says no credit card is required to start. The platform is open source and presented for researchers, including students and faculty conducting rapid or full systematic reviews. The listed academic plan includes unlimited collaborators. The homepage credits Milad Mirmoghtadaei, M.D. as developer.